Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Editorial: Cellular and Molecular Mechanisms of Immune Checkpoint Blockers in Anti-Leukemia/Lymphoma Immune Therapy Publisher



Ganjalikhanihakemi M1 ; Xu L2 ; Bazhin AV7, 8
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Immunology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Institute of Hematology, School of Medicine, Key Laboratory for Regenerative Medicine of Ministry of Education, Jinan University, Guangzhou, China
  3. 3. Institute of Molecular Medicine, Sechenov First Moscow State Medical University, Moscow, Russian Federation
  4. 4. Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow, Russian Federation
  5. 5. Department of Biotechnology, Sirius University of Science and Technology, Sochi, Russian Federation
  6. 6. Faculty of Health and Medical Sciences, University of Surrey, Guildford, United Kingdom
  7. 7. Department of General, Visceral, and Transplant Surgery, Ludwig-Maximilians-University Munich, Munich, Germany
  8. 8. German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany

Source: Frontiers in Oncology Published:2022


Abstract

[No abstract available]
Related Docs
1. Immune Checkpoint Inhibition for the Treatment of Cancers: An Update and Critical Review of Ongoing Clinical Trials, Clinical Immunology (2021)
2. Comparison of Laboratory Methods for the Clinical Follow up of Checkpoint Blockade Therapies in Leukemia: Current Status and Challenges Ahead, Frontiers in Oncology (2022)
3. Nivolumab Plus Ipilimumab Combination Therapy in Cancer: Current Evidence to Date, International Immunopharmacology (2023)
Experts (# of related papers)
Mazdak Ganjalikhani Hakemi (1)